Femasys Reports 40.8% Sales Growth, Secures $12M Financing, and Extends Cash Runway Amidst Delisting Concerns

summarizeSummary

Femasys Inc. reported a 40.8% increase in 2025 sales to $2.29 million and provided a corporate update, including the completion of a $12 million financing round and a cash runway into Q3 2026, amidst ongoing net losses and efforts to address Nasdaq delisting.

check_boxKey Events

• Reports 40.8% Sales Growth

  Femasys Inc. announced a 40.8% increase in sales, reaching $2.29 million for the year ended December 31, 2025, primarily driven by FemBloc sales.

• Secures $12 Million Financing

  The company completed a $12 million financing round, strengthening its balance sheet to support ongoing clinical and commercial execution.

• Provides Cash Runway Guidance

  Cash and cash equivalents were approximately $9.3 million as of December 31, 2025, with the company expecting this to fund operations into the third quarter of 2026.

• Advances Product Pipeline

  Key milestones include initiating patient enrollment in the FINALE pivotal trial for FemBloc, securing FDA 510(k) clearance for FemVue, and receiving CPT code approval for FemaSeed.

auto_awesomeAnalysis

This 8-K provides the official financial results for 2025 and a comprehensive corporate update. The 40.8% increase in sales to $2.29 million is a significant positive for this micro-cap company, demonstrating traction for its products. While the company continues to operate at a net loss, the successful completion of a $12 million financing round and the current cash position, expected to fund operations into Q3 2026, are critical for extending its operational runway. These financial updates are particularly important given the company's recent announcement of a special meeting to vote on a reverse stock split to address Nasdaq delisting concerns. The filing also highlights several key product development, regulatory, and commercial milestones, indicating progress in its core business areas.